Clinical Trial Search

Primary: Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 Weeks — 28; 25; 27 participants

Primary: Overall Survival at 18 Months — 63 percentage of participants

Primary: Durable Response Rate — 2.1; 16.3 percentage of participants — p=<0.0001

Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0-inf]) in the Fasted and Fed States — 115; 351 micrograms*hour per milliliter (µg*h/mL)

Primary: Change From Baseline in Ulcer Surface Area at Week 12 — -7.96 cm^2

Primary: Change From Baseline in HbA1c at 26 Weeks — -1.48; -1.22; -0.92 percentage of HbA1c — p=<0.001

Primary: Percentage of Participants Who Underwent Gynecologic Surgery — 42; 32; 26 percentage of participants

Primary: Live Birth Rate — 13; 5; 12 participants — p=0.06

Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants

Primary: Number of Participants With Adverse Events — 3; 3; 0; 0 participants

Primary: Total Mortality. — 173 participants

Primary: Change From Baseline to End of Treatment in Total International Prostate Symptom Score — -5.4; -6.2; -7.0; -6.5 units on a scale — p=0.001

Primary: The Primary Endpoint is the Proportion of Patients Maintained on Mitotane After 12 Consecutive Weeks of Therapy. A Positive Outcome Would be Seeing 50% or More Patients…

Primary: Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 75; 71.8; 71.7; 73.3 Percentage of participants

Primary: Change in PTSD Symptoms as Measured by the PCL — -7.33; -2.13 Units on a scale